Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial

• The trial enrolled 1,255 IPF patients and tested two doses; the 60 mg twice-daily dose significantly preserved lung function versus placebo, but the 120 mg dose missed its main goal
• Admilparant would be the first-of-its-kind LPA1 inhibitor for IPF, competing against existing treatments like Boehringer's Ofev and Roche's Esbriet
• Analyst Matt Phipps estimates blockbuster potential with $1.3 billion in 2032 sales, though complete safety and efficacy data are needed to fully assess commercial opportunity

Bristol Myers' Lung Disease Drug Succeeds at Lower Dose in Late-Stage Trial

Bristol Myers Squibb announced positive results from a late-stage trial of admilparant, an experimental treatment for idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. The trial enrolled 1,255 patients and tested two oral doses of the drug, which blocks the LPA1 protein receptor involved in lung scarring.

Key Results:

• The 60 mg twice-daily dose significantly outperformed placebo in preserving lung function after 52 weeks
• The higher 120 mg dose failed to meet the study's primary endpoint
• Both doses were well-tolerated with low discontinuation rates comparable to placebo

Market Implications:

William Blair analyst Matt Phipps projects admilparant could generate approximately $1.3 billion in sales by 2032, representing a blockbuster opportunity. If approved, admilparant would become the first LPA1 inhibitor to treat IPF, offering a new mechanism of action in a market currently dominated by Boehringer Ingelheim's Ofev and Jascayd, and Roche's Esbriet.

Analysts had previously tempered expectations due to safety concerns and are awaiting complete data to fully assess commercial potential. RBC analyst Trung Huynh noted that while Bristol Myers is well-positioned, investor attention will shift to upcoming trial results for the company's atrial fibrillation drug milvexian and Alzheimer's-related psychosis therapy Cobenfy.

Additional News:

Bristol Myers also reported positive trial results for its radiopharmaceutical cancer drug RYZ101. A separate late-stage study for progressive pulmonary fibrosis is expected in early 2027.

IPF causes irreversible lung scarring that thickens and stiffens tissue, progressively impairing breathing and lung function.